Key result
NT-proBNP serves as a promising biomarker for determining the prognosis of resistant hypertension, as its increased release acts as a compensatory response aimed at lowering blood pressure.
Why the study?
NT-proBNP may play a role in the development of resistant hypertension, but existing studies address this only indirectly and reported associations remain inconsistent.
NT-proBNP serves as a promising biomarker for the prognosis of resistant hypertension and may help guide targeted therapies like sacubitril/valsartan.
Modern medicine has successfully used the N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for many cardiovascular diseases (CVDs). According to a number of studies, NT-proBNP may also play a role in the development of resistant hypertension (RH), but the existing work addresses this issue only indirectly. In turn, RH causes serious damage to the economic and social spheres, worsening the quality of life of patients. Thus, the complexity of verification and treatment of RH, the inconsistency of the described associations of NT-proBNP and RH makes this topic more relevant than ever.
No takes yet. Share an insight, caveat, or question.
Nikolaev et al. (2022) conducted a review in Resistant hypertension. NT-proBNP was evaluated. NT-proBNP serves as a promising biomarker for determining the prognosis of resistant hypertension, as its increased release acts as a compensatory response aimed at lowering blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: